Clinical Trials Browser

NCT06704724 2026-05-22

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT05379985 2026-05-15

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Phase 1/2 Recruiting

754 enrolled

DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Gastrointestinal Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplastic Processes, Pancreatic Neoplasms, Thoracic Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT05462717 2026-05-15

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Phase 1 Active not recruiting

222 enrolled

GastrointestinalGynecologicThoracic

Appendiceal Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Stomach Neoplasms, Thoracic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Pancreatic Ductal

Clinical Trials

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

PACsign

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

ENACT

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

ResCPa

Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases

A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Using Tumor Models to Determine Treatments

DIRECT

Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC

An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

CanStem111P

PACAP-1

PDAC

ParvOryx02

The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer

OPT-1

Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Amatuximab for High Mesothelin Cancers

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas

QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer

A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

Continuous Monitoring on the General Ward

Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma

Atu027-I-02

A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer

Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer

According CTC to Compare the Influences of Different Methods to Remove the PDAC

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer